Cronos Jumps Premarket as Q3 Revenue Tops Consensus by 20%
CRON sits 65% above its 52-week low of $2.28 on elevated volume (2.0× avg).
Summary
Cronos reported Q3 2026 net revenue of $63.5M, up 75% year over year and well above the $52.8M consensus, driven by cannabis flower sales in Israel and Germany plus a stronger Israeli shekel. Adjusted EBITDA came in at $17.1M versus $9.7M expected, and net income of $17.8M beat the $11.1M consensus even though it fell about 37% year over year. Gross profit rose 76% to $32.3M on higher volumes and average selling prices, while operating expenses climbed about 24% to $23.3M. The beat follows the October 15 close of the €57.5M CanAdelaar acquisition, which added the largest licensed grower in the Netherlands' adult-use market and supports the international flower volume behind this quarter. Shares are trading near a 52-week high, so the bar was already elevated and the company cleared it on both revenue and EBITDA.
At the time of this announcement, CRON was trading at $3.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.28 to $3.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.